ecancermedicalscience

Short Communication

The current situation regarding the availability and accessibility of anticancer drugs for breast cancer in the Peruvian public health system

27 Apr 2021
Guillermo Valencia-Mesías, Patricia Rioja-Viera, Zaida Morante-Cruz, Yura Toledo-Morote, Silvia Neciosup-Delgado, Henry Gómez-Moreno

The availability of effective, accessible, safe and high-quality anticancer drugs for the medical treatment of cancer is fundamental in ensuring optimal healthcare in the public health system in Peru. The main objective is to assess the current situation regarding anticancer drugs (termed ‘high-cost’) for breast cancer, as well as an analysis of the possible factors which negatively impact access to the Peruvian public health systems.There are similarities in the availability of anticancer drugs, since most treatments are covered by the Peruvian Ministry of Health. EsSalud offers an extra monoclonal antibody (pertuzumab) in the metastatic treatment stage. Meanwhile, the National Institute of Neoplastic Diseases (INEN), mainly for metastatic disease, has relied on more tested treatments over the last year. An agreement has been reached with the armed forces, which will enable patients to receive oncology care at the INEN and, thereby, benefit from the use of high-cost drugs.

Related Articles

Felipe Andrés Cordero da Luz, Eduarda da Costa Marinho, Camila Piqui Nascimento, Lara de Andrade Marques, Patrícia Ferreira Ribeiro Delfino, Rafael Mathias Antonioli, Marcelo José Barbosa Silva, Rogério Agenor de Araújo
Mauro Daniel Spina Donadio, Dirce Maria Carraro, Giovana Tardin Torrezan, Celso Abdon Lopes de Mello
Tiago Cordeiro Felismino, Felipe Marcio Araujo Oliveira, Camilla Albina Zanco Fogassa, Silvia Nardozza Santerini, Victor Hugo Fonseca de Jesus, Rachel Simões Pimenta Riechelmann, Felipe José Fernandez Coimbra, Celso Abdon Lopes Mello
Soumitra Shankar Datta, Soumita Ghose, Manisha Ghosh, Amruta Jain, Sumedha Mandal, Sayan Chakraborty, Carlo Caduff